Klastersky J
Service de Médecine Interne et Laboratoire d'Investigation Clinique H. Tagnon, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Brussels, Belgium.
J Antimicrob Chemother. 1998 Jun;41 Suppl D:13-24. doi: 10.1093/jac/41.suppl_4.13.
The following aspects of the management of patients with granulocytopenia and fever are reviewed in this article: adaptation of initial antibiotic regimens to the recent changes in the most common causative pathogens (namely a change from Gram-negative bacteria to Gram-positive bacteria and fungi); subsequent modifications of the empirically administered treatments; improvement of the host's defence by reducing the duration of neutropenia; and indications for out patient therapy of febrile episodes.
